Univest
Univest
  • Markets

Wockhardt Q1 FY27 Results: Revenue Rs 929 Cr, PAT Rs 107 Cr and Key Highlights

  • August 11, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Wockhardt Q1 FY27 Results: Revenue Rs 929 Cr, PAT Rs 107 Cr and Key Highlights

Wockhardt Q1 FY27 results declared August 10, 2026. Revenue Rs 929 Cr (+25.88% YoY). PAT Rs 107 Cr (+199.07% YoY). CMP Rs 1931.2 (-4.44%).

Wockhardt Q1 FY27 results were declared on August 10, 2026 on a consolidated basis. Revenue expanded +25.88% YoY to Rs 929 Cr from Rs 738 Cr in Q1 FY26. The broader Nifty Pharma index reflected mixed sentiment during the quarter.

Operating profit stood at Rs 137 Cr (+756.25% YoY). PAT came in at Rs 107 Cr (+199.07% YoY), reflecting the key financial metrics of Wockhardt Q1 FY27 results.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Wockhardt Q1 FY27 Financial Highlights
  • Wockhardt Q1 FY27 Performance Analysis
  • Key Business Factors in Wockhardt Q1 FY27 Results
    • Revenue Expansion in Q1 FY27
    • Operating Margin Performance
    • PAT Trajectory and Profitability
  • Dividend Details
  • FY27 Outlook for Wockhardt
  • Wockhardt Stock Performance After Q1 FY27 Results
  • Key Risks for Wockhardt
    • Sector-Specific Risks
    • Valuation and Earnings Risk
    • Operational and Financial Risk
  • Conclusion
  • Frequently Asked Questions on Wockhardt Q1 FY27 Results
    • When were Wockhardt Q1 FY27 results declared?
    • What was Wockhardt revenue in Q1 FY27?
    • What was Wockhardt PAT in Q1 FY27?
    • Did Wockhardt declare a dividend in Q1 FY27?
    • What is the FY27 outlook for Wockhardt?
    • How did Wockhardt stock react to Q1 FY27 results?

Wockhardt Q1 FY27 Financial Highlights

Metric Q1 FY27 (Rs Cr) Q1 FY26 (Rs Cr) YoY Change
Wockhardt Revenue 929 738 +25.88%
Operating Profit 137 16 +756.25%
Net Profit (PAT) 107 -108 +199.07%
Reporting Basis Consolidated

Wockhardt Q1 FY27 Performance Analysis

Check the Univest Screener for Live Data on This Stock

Wockhardt Q1 FY27 results reflect exceptional fundamentals. Revenue momentum were evident with the top line reaching Rs 929 Cr for the April to June 2026 quarter.

Operating profit expanded +756.25% YoY. PAT of Rs 107 Cr reflects +199.07% YoY movement. Investors tracking Wockhardt Q1 FY27 results will note these as key FY27 milestones.

Key Business Factors in Wockhardt Q1 FY27 Results

Revenue Expansion in Q1 FY27

Wockhardt Q1 FY27 results show revenue expanding +25.88% YoY to Rs 929 Cr from Rs 738 Cr in Q1 FY26. Volume-led growth and market share gains in the Pharmaceuticals segment drove the uptick.

Operating Margin Performance

Operating profit in Wockhardt Q1 FY27 results stood at Rs 137 Cr (+756.25% YoY). Better cost absorption and product mix improvement contributed to the operating performance.

PAT Trajectory and Profitability

PAT in Wockhardt Q1 FY27 results was Rs 107 Cr (+199.07% YoY), reflecting the company’s improving financial health.

Dividend Details

No dividend was declared alongside Wockhardt Q1 FY27 results. Earnings are being channelled toward operational reinvestment and working capital.

FY27 Outlook for Wockhardt

Wockhardt is positioned to sustain growth momentum through FY27, backed by order visibility, operational improvements, and sector tailwinds in the pharmaceuticals space. Investors tracking Wockhardt Q1 FY27 results should consult a SEBI-registered financial advisor before making decisions.

Wockhardt Stock Performance After Q1 FY27 Results

Download the Univest iOS App or Univest Android App to track Wockhardt live price and get daily stock recommendations.

Wockhardt shares were trading lower at Rs 1931.2 (-4.44%) on August 10, 2026, reflecting investor sentiment on Wockhardt Q1 FY27 results and the near-term sector outlook. The CMP of Rs 1931.2 on the results date reflects broader sentiment toward the pharmaceuticals space.

Key Risks for Wockhardt

Sector-Specific Risks

USFDA regulatory actions, generic pricing pressure, and API cost inflation remain core risks.

Valuation and Earnings Risk

Valuation risk remains if quarterly growth fails to sustain over the next two to three quarters.

Operational and Financial Risk

Subsidiary-level underperformance could drag consolidated PAT lower in subsequent quarters.

Conclusion

Wockhardt Q1 FY27 results reflect exceptional performance with revenue at Rs 929 Cr and PAT at Rs 107 Cr on a Consolidated basis. Sector tailwinds and operational discipline will shape the FY27 trajectory. Investors should review management commentary before taking any position.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Wockhardt Q1 FY27 Results

When were Wockhardt Q1 FY27 results declared?

Ans. Wockhardt Q1 FY27 results were declared on August 10, 2026, covering the April–June 2026 quarter on a Consolidated basis.

What was Wockhardt revenue in Q1 FY27?

Ans. Revenue in Wockhardt Q1 FY27 results was Rs 929 Cr, +25.88% YoY from Rs 738 Cr in Q1 FY26.

What was Wockhardt PAT in Q1 FY27?

Ans. Net profit in Wockhardt Q1 FY27 results was Rs 107 Cr (+199.07% YoY).

Did Wockhardt declare a dividend in Q1 FY27?

Ans. No dividend was announced alongside Wockhardt Q1 FY27 results. Refer to official NSE and BSE announcements for future dividend updates.

What is the FY27 outlook for Wockhardt?

Ans. Management has guided revenue growth and margin improvement for FY27. Sector demand and execution will be key monitorables.

How did Wockhardt stock react to Q1 FY27 results?

Ans. Wockhardt shares were lower at Rs 1931.2 (-4.44%) on August 10, 2026. Consult a SEBI-registered financial advisor before acting on price movements.



News
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply